Mission and Technology

General

Untitled design.jpg

Annual economic burden of vision loss and eye disorders, including falls, cognitive decline and depression is estimated to be $139 B2 in US and >$500 B3  worldwide

Wet Macular Degeneration (AMD), Diabetic Macular Edema (DME) , Diabetic Retinopathy (DR) ,
Retinal Vein Occlusion (RVO) account for over over 13.7 million patients in US
1 and 96 million patients per year worldwide, 

Market size growing at 8% rate
per year

 
 

Indications

Diabetic Retinopathy (DR)

 


High blood sugar levels cause damage to blood vessels in the retina and blood vessels can swell and leak, stopping blood from passing through and leading to loss of visual acuity.

1.5 Million Patients in the US 2

139 Million Patients World Wide 3

Wet Age-Related Macular Degeneration (wAMD)

Edema caused by abnormal vasculature growth which ultimately results in the loss of visual function.

1.1 Million Patients in the US 2

20 Million Patients World Wide 5

Macular Edema

Secondary to Retinal Vein Occlusion (RVO)

Characterized by a retinal vein blockage, which selectively leads to edema formation and loss of visual acuity.

1.1 Million Patients in the US 2

16.4 Million Patients World Wide 6

Diabetic Macular Edema (DME)

 

A complication of diabetes that manifests as inflammation, edema and hard exudates in the macula and leads to loss of visual acuity. 

1.5 Million Patients in the US 2

21 Million Patients World Wide 4

Screen Shot 2022-02-18 at 10.46.04 AM.png
Three Generations

More Information regarding Retinal Diseases

Retinal diseases are primarily correlated with diabetes and or aging

Screen Shot 2022-02-10 at 11.12.05 AM.png

Vision loss can be rapid and severe if untreated

Untitled design-2.jpg

Abnormal blood vessels that bleed and leak fluid grow under and into the macula, the central part of the retina

Blurry People
 

Current Standard of Care

Current Standard of Care (SoC) is intravitreal injections of anti-VEGF agents that need to be given as frequently as once a month, for an indefinite period 

Woman Having Eyes Examined

Intravitreal (IVT) injections of anti-VEGF drugs (Lucentis/ranibizumab from Roche/Genentech or Elyea/aflibercept from Regeneron/Bayer) by a retina specialist once every 1-2 months, into one or both eyes, often for life 

Drug cost per injection: $1950+ (not including physician fees) for branded

Benefit of regular pharmacologic treatment:
Significant recovery of vision and prevention of vision loss, leading to better lives

 

Optigo Bio's Solution

Untitled design.jpg

Address challenges of Current Standard of Care through novel proprietary approach for anti-VEGF treatments to extend longevity.

 

Reduce injection frequency from 4-12 weeks to 6-12 months

Decrease drug costs through lower injection frequency 

Reduce burden on retina specialists through lower injection frequency

Improve patient compliance through lower injection frequency

Decrease burden on clinics through lower injection frequency 

Decrease burden on payor  through lower volume of reimbursement claims

 

References:

1. Based on 2015-2020 public filings from Regeneron, Roche and Novartis for combined indications

2. https://www.gene.com/stories/retinal-diseases-fact-sheet

3. About 30% of all diabetes patients get Diabetes Retinopathy. 2019 there were 463 M patients

4. International Diabetes Information, Diabetes Macular Edema DME Report 

5. https://www.brightfocus.org/macular/article/age-related-macular-facts-figures

6. https://retinatoday.com/articles/2018-apr/rvo-overview

7. Market Scope 2019  Retinal Pharmaceuticals Market Report